Drug development

New research could help address heart problems in diabetics

Research published in Experimental Physiology shows that diabetes-induced changes in heartbeat are primarily regulated by the β1-adrenoceptor. This discovery, once confirmed in humans, may lead to better treatment of heart problems in diabetics by enabling more targeted drugs to be produced.

A new discovery in certain receptors of diabetes patients may give insights on...
A new discovery in certain receptors of diabetes patients may give insights on how to counteract heart problems.
Source: Universitätsklinikum Heidelberg

Patients with type 2 diabetes can have problems with the regulation of their heartbeat. The heartbeat is partly regulated by receptors called beta-adrenoceptors. There are two different forms, the β1 and β2, and each has a different function. The study found that the diabetes-induced changes in heartbeat are predominantly regulated by the β1-adrenoceptor, and not the β2-adrenoceptor.

Beta-blockers block hormones like adrenaline and can be used to decrease heart rate and blood pressure in the treatment of conditions such as angina or high blood pressure. Some beta-blockers are not effective in reducing the heartbeat of diabetics and can even worsen the blood glucose levels of patients. It is not known which beta-adrenoceptor type is responsible for these effects. This study suggests that beta-blockers targeting the β1-adrenoceptor would be more effective for diabetics.

The researchers implanted two devices into a rat model of diabetes. The first device measured blood pressure and heartbeat, and the second device injected drugs that reduce heartbeat by targeting the beta-adrenoceptors. This approach allowed the researchers to distinguish between the contributions of the two different beta-adrenoceptors (β1 and b2). Regis Lamberts, corresponding author said, 'This study provides novel insight into the pathological basis of heart rate dysregulation in type 2 diabetes. This could help us develop drugs to better address heart problems in diabetics.'

 

Source: The Physiological Society

24.05.2017

Read all latest stories

Related articles

Photo

At atomic accuracy

Glulisine research could improve diabetes treatment

For the first time, scientists have come up with a precise atomic level explanation for why glulisine - a commonly used medication to treat diabetes - is faster acting than insulin. The findings,…

Photo

Surprising side-effects

A new cancer drug (that fights obesity and diabetes, too)

Eric Prossnitz, PhD, from the University of New Mexico Health Services and his team hope to help 93 million obese Americans fight their fat. In a paper published in Science Translational Medicine,…

Photo

Dysbiosis treatment

New prebiotics: benefits without downsides?

Prebiotics are currently a preferred treatment for certain metabolic disorders, as they can restore the balance of dysfunctional gut microbiota, and improve the body’s metabolism. However, these…

Related products

Lifotronic - FA-160 Immunofluorescence Analyzer

Other

Lifotronic - FA-160 Immunofluorescence Analyzer

Lifotronic Technology Co., Ltd
Analyticon Biotechnologies AG - Urilyzer 100 Pro

Urinalysis

Analyticon Biotechnologies AG - Urilyzer 100 Pro

Analyticon Biotechnologies AG
Fujifilm Wako – Autokit Total Ketone Bodies Assay

Clinical Chemistry

Fujifilm Wako – Autokit Total Ketone Bodies Assay

FUJIFILM Wako Chemicals Europe GmbH
Greiner – VACUETTE FC Mix tube

Blood Glucose

Greiner – VACUETTE FC Mix tube

Greiner Bio-One
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Subscribe to Newsletter